A major wrongful death lawsuit has been filed alleging defects in Abbott Laboratories' (NYSE:ABT) FreeStyle Libre 3 and Libre 3 Plus glucose monitoring systems. The claim links the products to seven ...

Abbott is the name behind many well-known products.

In a decisive move to fund one of its most significant strategic acquisitions in recent years, Abbott Laboratories has launched a massive $20 billion bond offering. The proceeds are earmarked to ...

Abbott Laboratories is delivering double-digit percentage earnings growth along with a dependable dividend.

Diagnostics market is projected to reach a valuation of approximately US$ 105.22 billion, driven by an 8.60% CAGR from 2025. This robust growth is fueled by high demand for rapid and accessible ...

Exact Sciences Corp. (NASDAQ:EXAS) is one of 15 stocks with the biggest hedge fund momentum, after gaining 31 hedge fund ...

Researchers have known for decades that different brands of lab machines produce different results. The fix is easy — but not ...

Abbott Labs is looking to raise about $20 billion from a bond sale to help fund its acquisition of Exact Sciences, marking one of the biggest offerings this year.

The City Council approved a proposal that gives CPD access to grant funding to buy new oral drug testing equipment. Here's what to know about the system.

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Officials and companies are betting that small nuclear reactors could help provide needed power to the Texas grid while bringing investment and jobs.

MUSC hospital 1st South Carolina to use Abbott’s rapid bedside heart attack test, delivering results in 15 minutes to speed emergency care.